Overview and Key Takeaways
Chloroquine is a long-standing antimalarial that remains first-line in regions without Plasmodium falciparum resistance, but widespread resistance limits its use in many areas. It works by disrupting heme detoxification in the parasite, leading to parasite death, and is valued for oral convenience and low cost in susceptible regions. This page explains when chloroquine is appropriate, how to take it, resistance patterns, side effects, and alternatives for treatment and prevention. The information below is intended to support informed conversations with clinicians and to guide consistent, evidence-based decision-making.
What Is Chloroquine and Its Historical Role
Chloroquine is a synthetic 4-aminoquinoline drug introduced in the 1940s that became a cornerstone of malaria control due to its reliability, oral administration, and favorable safety profile when used correctly. Historically, it enabled expansion of malaria-endemic regions by making prophylaxis and treatment practical at scale. The drug accumulates in the parasite’s digestive vacuole, raising pH and interfering with heme polymerization, which is lethal to the blood-stage parasite. Although widespread resistance emerged in Plasmodium falciparum during the late 20th century, chloroquine remains an important tool in specific geographic and epidemiological contexts.
How Chloroquine Works at the Biological Level
Chloroquine interferes with the parasite’s heme detoxification pathway. During hemoglobin digestion, the parasite produces toxic heme (hematin); normally heme is polymerized into harmless hemozoin. Chloroquine raises the pH of the digestive vacuole, inhibiting this process and allowing free heme to accumulate to lethal levels. The drug also interferes with parasite enzymes and nucleic acid metabolism, contributing to its blood-stage schizonticidal activity against susceptible strains of Plasmodium. These mechanisms explain why chloroquine is effective against blood-stage infections but does not target liver-stage forms (hypnozoites), which is why it is not used for radical cure of Plasmodium vivax or Plasmodium ovale without a partner drug.
Key Pharmacologic Points
- Rapidly absorbed after oral administration, with wide tissue distribution including liver, spleen, and macrophages.
- Long half-life (about 30–50 hours), supporting once-weekly prophylaxis when used without resistance.
- High intracellular concentrations in monocytes and macrophages, contributing to both antimalarial and immunomodulatory effects.
- Does not effectively reach insecticidal concentrations in mosquitoes at typical dosing, so it is not used for vector control.
Geographic Use and Resistance Patterns
The utility of chloroquine for treatment depends on local resistance patterns. In much of sub-Saharan Africa, chloroquine resistance in P. falciparum is widespread, making it unreliable for treatment. In contrast, chloroquine remains effective and first-line for P. vivax in parts of Central America, the Caribbean, Central Asia, and the Middle East where resistance is uncommon. In these regions, chloroquine is used for acute treatment of both uncomplicated and severe malaria (when injectable artesunate is not available) and for prophylaxis, often in combination with primaquine or other agents for radical cure. Global resistance maps and national guidelines should always be consulted before prescribing.
Dosing for Treatment and Prevention
For treatment of uncomplicated malaria in susceptible areas, chloroquine is typically given as an initial high dose followed by a lower maintenance dose. In areas without resistance, adults may receive a single dose based on body weight, often 1000 mg base (600 mg salt) followed by 500 mg base (300 mg salt) at 6, 18, and 24 hours. For children, weight-based dosing is used with careful measurement. For prophylaxis, the standard is once-weekly dosing starting before travel, continuing during exposure, and for four weeks after leaving the endemic area. Adherence to the full post-travel course is critical to prevent late infection. Dosing adjustments are considered in renal impairment, and chloroquine is generally avoided in pregnancy unless the benefit clearly outweighs risks.
Example Dosing Regimens (Adults, Chloroquine Base)
| Purpose | Dose (mg base) | Schedule | Context |
|---|---|---|---|
| Treatment (susceptible regions) | 1000 | Day 1 (single or divided) | Acute uncomplicated malaria |
| Follow-up doses | 500 | Day 2, 3 (6–12 hourly) | Ensure cure in susceptible areas |
| Prophylaxis | 500 | Once weekly | Start 1–2 weeks before, during, and 4 weeks after travel |
| Severe malaria (if artesunate unavailable) | 4800 over 24h (loading then maintenance) | Intravenous or oral split regimen | Hospital care in resource-limited settings |
Safety, Contraindications, and Monitoring
Chloroquine is generally well tolerated at prophylactic and therapeutic doses, but toxicity can occur with overdose or long-term use at high doses. Common adverse effects include headache, nausea, abdominal pain, and pruritus. Serious effects are rare but can include retinopathy with cumulative toxicity (typically after years of high-dose use), cardiomyopathy, and exacerbation of psoriasis or porphyria. ECG changes such as QT prolongation may occur, especially in overdose or when combined with other QT-prolonging drugs. Chloroquine is contraindicated in individuals with known hypersensitivity and used with caution in those with glucose-6-phosphate dehydrogenase (G6PD) deficiency, although hemolysis is usually mild compared to other antimalarials. Baseline and periodic ophthalmologic exams are recommended for long-term users. Drug interactions include potential augmentation of neuromuscular blockade and effects with concomitant QT-prolonging medications.
When Chloroquine Is Not Enough: Alternatives and Combination Strategies
In areas with chloroquine-resistant P. falciparum, artemisinin-based combination therapies (ACTs) are the standard treatment. For prophylaxis in many regions, atovaquone-proguanil, doxycycline, or mefloquine may be preferred depending on resistance patterns and traveler profiles. For vivax malaria in chloroquine-susceptible areas, chloroquine effectively treats the blood stage, but primaquine or tafenoquine is required to clear liver hypnozoites and prevent relapse; testing for G6PD deficiency is essential before adding these agents. In pregnant travelers, chloroquine may be an option in susceptible regions, while mefloquine or atovaquone-proguanil are considered in areas with resistance. The choice of antimalarial should be individualized based on destination, resistance patterns, comorbidities, and personal factors, and guided by current national and international recommendations.
Practical Points for Patients and Travelers
When considering chloroquine for malaria, plan ahead: obtain region-specific guidance before travel, start prophylaxis at the recommended time, use precise weight-based dosing, and complete the post-travel course to prevent late illness. Dispense clear instructions on what to do if a dose is missed and when to seek care for possible side effects or treatment failure. Encourage prompt reporting of persistent fever or illness after return, as this may indicate a resistant infection or alternative diagnosis. Remember that chloroquine does not prevent other mosquito-borne illnesses and that bite avoidance and bed nets remain essential. Shared decision-making, informed by up-to-date susceptibility data and individual risk profiles, leads to safer and more effective malaria prevention and treatment.